(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(-0.82%) $83.16
(-1.16%) $1.619
(-0.43%) $2 337.00
(0.93%) $27.51
(0.56%) $927.30
(-0.16%) $0.933
(-0.15%) $11.01
(-0.24%) $0.798
(0.00%) $92.17
Live Chart Being Loaded With Signals
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz...
Stats | |
---|---|
Dagens volum | 1.46M |
Gjennomsnittsvolum | 1.63M |
Markedsverdi | 190.64B |
EPS | $0 ( 2024-04-23 ) |
Neste inntjeningsdato | ( $1.850 ) 2024-07-16 |
Last Dividend | $3.47 ( 2023-03-09 ) |
Next Dividend | $0 ( N/A ) |
P/E | 22.15 |
ATR14 | $0.0230 (0.02%) |
Volum Korrelasjon
Novartis AG Korrelasjon
10 Mest positive korrelasjoner |
---|
10 Mest negative korrelasjoner |
---|
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Novartis AG Korrelasjon - Valuta/Råvare
Novartis AG Økonomi
Annual | 2023 |
Omsetning: | $46.66B |
Bruttogevinst: | $34.19B (73.27 %) |
EPS: | $7.15 |
FY | 2023 |
Omsetning: | $46.66B |
Bruttogevinst: | $34.19B (73.27 %) |
EPS: | $7.15 |
FY | 2022 |
Omsetning: | $51.83B |
Bruttogevinst: | $36.34B (70.12 %) |
EPS: | $3.19 |
FY | 2021 |
Omsetning: | $52.88B |
Bruttogevinst: | $37.01B (69.99 %) |
EPS: | $10.71 |
Financial Reports:
No articles found.
Novartis AG Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$3.47 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $0.966 | 2000-11-14 |
Last Dividend | $3.47 | 2023-03-09 |
Next Dividend | $0 | N/A |
Payout Date | 2023-03-20 | |
Next Payout Date | N/A | |
# dividends | 23 | -- |
Total Paid Out | $44.60 | -- |
Avg. Dividend % Per Year | 2.46% | -- |
Score | 4.08 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 5.42 | |
Div. Directional Score | 7.88 | -- |
Year | Amount | Yield |
---|---|---|
2000 | $0.966 | 2.96% |
2001 | $0.450 | 1.12% |
2002 | $0.468 | 1.46% |
2003 | $0.627 | 1.89% |
2004 | $0.722 | 1.57% |
2005 | $0 | 0.00% |
2006 | $0.801 | 1.50% |
2007 | $0.969 | 1.67% |
2008 | $1.319 | 2.42% |
2009 | $1.541 | 3.11% |
2010 | $1.780 | 3.38% |
2011 | $2.11 | 3.56% |
2012 | $2.20 | 3.78% |
2013 | $2.27 | 3.56% |
2014 | $2.44 | 3.10% |
2015 | $2.52 | 2.73% |
2016 | $2.47 | 2.88% |
2017 | $2.46 | 3.38% |
2018 | $2.67 | 3.15% |
2019 | $2.57 | 3.06% |
2020 | $3.04 | 3.20% |
2021 | $3.38 | 3.58% |
2022 | $3.36 | 3.82% |
2023 | $3.47 | 3.76% |
2024 | $0 | 0.00% |
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
LOMA | Dividend Knight | 2023-06-30 | Quarterly | 2 | 5.23% | 8.53 |
NCZ | Dividend Royal | 2024-02-09 | Monthly | 22 | 7.79% | 8.50 |
KIO | Dividend Royal | 2023-12-14 | Monthly | 12 | 7.05% | 8.50 |
SCM | Dividend King | 2023-12-15 | Monthly | 13 | 7.08% | 8.50 |
SJT | Dividend Royal | 2023-11-29 | Monthly | 39 | 12.52% | 8.50 |
GOF | Dividend Royal | 2023-11-14 | Monthly | 18 | 8.03% | 8.50 |
SRV | Dividend Royal | 2023-12-04 | Monthly | 18 | 7.53% | 8.50 |
VGI | Dividend Royal | 2024-02-09 | Monthly | 13 | 7.36% | 8.50 |
PHK | Dividend Royal | 2023-11-10 | Monthly | 22 | 6.88% | 8.50 |
JQC | Dividend Royal | 2023-11-14 | Monthly | 22 | 6.56% | 8.50 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.307 | 1.500 | 3.86 | 5.79 | [0 - 0.5] |
returnOnAssetsTTM | 0.162 | 1.200 | 4.61 | 5.54 | [0 - 0.3] |
returnOnEquityTTM | 0.346 | 1.500 | 7.27 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.342 | -1.000 | 6.58 | -6.58 | [0 - 1] |
currentRatioTTM | 0.903 | 0.800 | -0.485 | -0.388 | [1 - 3] |
quickRatioTTM | 0.613 | 0.800 | -1.102 | -0.881 | [0.8 - 2.5] |
cashRatioTTM | 0.323 | 1.500 | 9.31 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.273 | -1.500 | 5.45 | -8.17 | [0 - 0.6] |
interestCoverageTTM | 12.32 | 1.000 | 6.55 | 6.55 | [3 - 30] |
operatingCashFlowPerShareTTM | 6.73 | 2.00 | 7.76 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 4.96 | 2.00 | 7.52 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.649 | -1.500 | 7.40 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.726 | 1.000 | 1.237 | 1.237 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.219 | 1.000 | 7.61 | 7.61 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.534 | 1.000 | 8.14 | 8.14 | [0.2 - 2] |
assetTurnoverTTM | 0.526 | 0.800 | 9.83 | 7.86 | [0.5 - 2] |
Total Score | 10.33 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 13.06 | 1.000 | 8.78 | 0 | [1 - 100] |
returnOnEquityTTM | 0.346 | 2.50 | 8.24 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 4.96 | 2.00 | 8.35 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 3.88 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 6.73 | 2.00 | 7.76 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.342 | 1.500 | 6.58 | -6.58 | [0 - 1] |
pegRatioTTM | -3.02 | 1.500 | -10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.277 | 1.000 | 5.57 | 0 | [0.1 - 0.5] |
Total Score | 5.42 |
Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.